ARCH Venture Partners has announced the closing of ARCH Venture Fund XII, with $2.975 billion to invest in the creation, development and funding of early stage biotechnology companies.\u00a0\n\n\n\nThe new fund follows the January 2021 announcement of the $1.941 billion ARCH Venture Fund XI.\n\n\n\n\u201cAll the fundamental innovations in biotechnology are accelerating, with huge promise for new preventive, disease-modifying, and even curative treatments,\u201d said ARCH co-founder and managing director Robert Nelsen.\n\n\n\n\u201cScience doesn\u2019t care what markets are doing, and science moves forward. With over 35 years of venture experience, ARCH has been creating and consolidating companies for the long term. We would like to thank our limited partners for supporting our twelfth fund.\u201d\u00a0\n\n\n\nBreakthrough technologies\n\n\n\nARCH investments made from Fund XII will reflect the firm\u2019s focus on companies formed around breakthrough technologies. This means investing in early stage biotech companies with potential to solve some of the biggest health challenges in areas including infectious disease, mental health, immunology, oncology, neurology, age-related diseases, manufacturing, clinical trials, genomic and biological tools, data sciences, and ways to reimagine diagnostics and therapies. \n\n\n\n\u201cOur approach has always been to pair great science with remarkable, proven teams to build disruptive companies. We believe in this model now more than ever. The science happening today is simply stunning and provides a broad base of innovation and discovery to bring forward,\u201d said ARCH managing director Kristina Burow.\n\n\n\n\u201cARCH has the team, network, track record and insights to build the next wave of high impact and highly valued life science and health care sector leaders. We plan to do just that by working for our limited partners and working with our portfolio companies,\u201d added ARCH co-founder and managing director Keith Crandell.\n\n\n\nARCH Venture Partners is one of the largest early-stage technology venture firms in the U.S. It invests primarily in companies it co-founds with leading scientists and entrepreneurs, bringing innovations in life sciences and physical sciences to market.